keyword
MENU ▼
Read by QxMD icon Read
search

Denosumab discontinue treatment

keyword
https://www.readbyqxmd.com/read/29725863/persistence-of-and-switches-from-teriparatide-treatment-among-women-and-men-with-osteoporosis-in-the-real-world-a-claims-database-analysis
#1
Tomoko Usui, Masaru Funagoshi, Kahori Seto, Kazuki Ide, Shiro Tanaka, Koji Kawakami
This study investigated the real-world persistence rate and switches of teriparatide-treated patients using a claims database in Japan. The persistence rate of teriparatide at 12 months was 34.9%, and approximately one-third of the patients were not treated with any osteoporosis drugs after teriparatide. Improvement in persistence and switches are desired. PURPOSE: We aimed to elucidate the persistence rates and switches before and after teriparatide treatment in real-world osteoporosis patients based on data from a medical claims database in Japan...
May 3, 2018: Archives of Osteoporosis
https://www.readbyqxmd.com/read/29720299/effects-of-denosumab-after-treatment-discontinuation-a-review-of-the-literature
#2
Maryam Iranikhah, Crystal Deas, Pilar Murphy, Maisha Kelly Freeman
OBJECTIVE: To review and summarize studies on the effects of denosumab on bone mineral density following the discontinuation of therapy. DATA SOURCES: A search of PubMed (1966-July 2017) and International Pharmaceutical Abstracts (1970-July 2017) was conducted using the Medical Subject Headings (MeSH) terms denosumab, osteoporosis, and withholding treatment in combination with free term searches including the words drug holiday, discontinue, discontin*, and drug discontinuation...
March 1, 2018: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/29694685/effects-of-24-months-of-treatment-with-romosozumab-followed-by-12-months-of-denosumab-or-placebo-in-postmenopausal-women-with-low-bone-mineral-density-a-randomized-double-blind-phase-2-parallel-group-study
#3
Michael R McClung, Jacques P Brown, Adolfo Diez-Perez, Heinrich Resch, John Caminis, Paul Meisner, Michael A Bolognese, Stefan Goemaere, Henry G Bone, Jose R Zanchetta, Judy Maddox, Sarah Bray, Andreas Grauer
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased BMD in postmenopausal women with low BMD (NCT00896532). Herein we report the study extension evaluating 24 months treatment with romosozumab, discontinuation of romosozumab, alendronate followed by romosozumab, and romosozumab followed by denosumab. Postmenopausal women age 55-85 years with a lumbar spine (LS), total hip (TH), or femoral neck T-score ≤-2.0 and ≥-3.5 were enrolled and randomly assigned to placebo, one of five romosozumab regimens (70mg, 140mg, 210mg monthly [QM]; 140mg Q3M; 210mg Q3M) for 24 months, or open-label alendronate for 12 months followed by romosozumab 140mg QM for 12 months...
April 25, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29691303/therapy-of-endocrine-disease-denosumab-versus-bisphosphonates-for-the-treatment-of-postmenopausal-osteoporosis
#4
Athanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras
The most widely used medications for the treatment of osteoporosis are currently bisphosphonates and denosumab. Both are antiresorptives, thus targeting the osteoclast and inhibiting bone resorption. Denosumab achieves greater suppression of bone turnover and greater increases of bone mineral density (BMD) at all skeletal sites, both in naïve and pre-treated patients. No superiority on fracture risk reduction has been documented so far. In long-term administration, bisphosphonates reach a plateau in BMD response after 2-3 years, especially at the hip, while BMD increases progressively for as long as denosumab is administered...
April 24, 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29680853/osteonecrosis-of-the-jaw-in-patients-traited-by-denosumab-for-malignant-bone-disease-descriptive-study-on-9-cases
#5
R Lan, M Hadj-Saïd, J-M Foletti, E Massereau, C Chossegros
BACKGROUND: This study examines the epidemiological and clinical characteristics and therapeutic outcomes in patients with denosumab related-osteonecrosis of the jaw (DRONJ). MATERIAL AND METHODS: The patients included are all being monitored by three oral and maxillofacial surgery departments for an osteonecrosis of the jaw (ONJ) linked to denosumab alone for the treatment of malignant bone disease between 2010 and 2016. Clinical and epidemiological data of these patients was indexed and characteristics of the DRONJ were analyzed...
April 22, 2018: Medicina Oral, Patología Oral y Cirugía Bucal
https://www.readbyqxmd.com/read/29583083/postmenopausal-osteoporosis-a-clinical-review
#6
Nelson B Watts
In postmenopausal women, osteoporotic fractures are more common than stroke, myocardial infarction, and breast cancer combined, and fractures can be costly and result in disability or death. Because there are no signs or symptoms of osteoporosis other than fracture, risk assessment is necessary to identify those at higher risk for clinical events. For women, a clinical fracture risk assessment (FRAX) is appropriate at menopause. Bone mineral density (BMD) measurement is recommended for women at age 65, and earlier for those who have risk factors...
March 27, 2018: Journal of Women's Health
https://www.readbyqxmd.com/read/29576576/successful-conservative-treatment-of-jaw-osteonecrosis-caused-by-denosumab-in-patients-with-multiple-bone-metastasis
#7
Noritaka Ohga, Jun Sato, Takuya Asaka, Masahiro Morimoto, Yutaka Yamazaki, Yoshimasa Kitagawa
We report a case of osteonecrosis of the jaw (ONJ) associated with denosumab therapy in a 62-year-old female patient being treated for bone metastases from breast cancer. Upon initial presentation at the Department of Oral Medicine, Hokkaido University Hospital, the patient's mandibular molar teeth were extracted because of severe periodontal disease. Two months later, epithelialization of the sockets was observed and treatment with anti-resorptive drugs was started for bone metastases. One year after tooth extraction, bone exposure in the right lower first molar region was observed, and stage 2 medication-related ONJ (MRONJ) was diagnosed...
2018: Journal of Oral Science
https://www.readbyqxmd.com/read/29546647/bone-best-papers-of-the-year-2017
#8
REVIEW
Michaël R Laurent
An overview of selected papers related to bone published in 2017 is provided. PURPOSE: This paper accompanies a lecture at the 2018 Belgian Bone Club annual Clinical Update Symposium held in Brussels on January 20th, discussing the best papers (in the opinion of the author) published in the previous year. METHODS: A PubMed search using the keyword "bone" and articles published in 2017. RESULTS: Hot topics include screening for osteoporosis, novel anabolic drugs such as romosozumab and abaloparatide for osteoporosis and rare metabolic bone diseases, as well as long-term efficacy of denosumab and possible risk of multiple vertebral fractures following its discontinuation...
March 15, 2018: Archives of Osteoporosis
https://www.readbyqxmd.com/read/29541794/effects-of-bone-remodeling-agents-following-teriparatide-treatment
#9
D Burkard, T Beckett, E Kourtjian, C Messingschlager, R Sipahi, M Padley, J Stubbart
Teriparatide is an anabolic therapy used to treat patients with osteoporosis and is only approved for 2 years of treatment. This is the first study to look at two common osteoporosis drugs in maintaining its beneficial effects: denosumab and zoledronic acid. Denosumab treatment was associated with the greatest increase in bone mineral density (BMD) at the femoral neck and lumbar spine, an amount that was statistically greater than no treatment and zoledronic acid treatment. INTRODUCTION: Teriparatide, a hallmark treatment for osteoporosis, has been shown to increase BMD and bone turnover...
March 14, 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29455249/multiple-vertebral-fractures-following-osteoporosis-treatment-discontinuation-a-case-report-after-long-term-odanacatib
#10
N Binkley, D Krueger, A E de Papp
INTRODUCTION: Case reports of women sustaining multiple vertebral fractures (VF) soon afterdenosumab discontinuation are accumulating. METHODS: We report a woman with five new vertebral fractures in ~8 months following discontinuation of long-term odanacatib (ODN), an experimental cathepsin K inhibitor. RESULTS: DXA examination demonstrated an ~12% decline in bone mineral density (BMD) and ~9% decline in trabecular bone score (TBS) since ODN discontinuation...
April 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29435849/denosumab-a-review-in-postmenopausal-osteoporosis
#11
Emma D Deeks
Denosumab (Prolia® ; Pralia® ) is a human monoclonal antibody targeting the key bone resorption mediator RANKL. The drug is administered via subcutaneous injection once every 6 months and is approved for various indications, including the treatment of postmenopausal (PM) women with osteoporosis at increased/high risk of fracture or failure/intolerance of other osteoporosis therapies (indications featured in this review). Denosumab showed benefit in several phase 3 or 4 studies in PM women with osteoporosis or low bone mineral density (BMD), including the pivotal 3-year double-blind FREEDOM trial and its 7-year open-label extension...
February 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29396698/vertebral-fractures-following-denosumab-discontinuation-in-patients-with-prolonged-exposure-to-bisphosphonates
#12
Liana Tripto-Shkolnik, Vanessa Rouach, Yonit Marcus, Pnina Rotman-Pikielny, Carlos Benbassat, Iris Vered
Denosumab (DMAB) efficacy for treatment of osteoporosis was demonstrated in a pivotal trial with a reduction in vertebral and hip fractures during 3 years, and fracture risk reduction was sustained up to 10 years in an extension study. DMAB causes potent yet reversible inhibition of bone resorption. Bone density declines rapidly upon discontinuation and bone turnover markers increase above baseline in a rebound fashion. Spontaneous multiple vertebral fractures after DMAB discontinuation were recently reported...
February 2, 2018: Calcified Tissue International
https://www.readbyqxmd.com/read/29380013/bone-mineral-density-changes-after-1-year-of-denosumab-discontinuation-in-postmenopausal-women-with-long-term-denosumab-treatment-for-osteoporosis
#13
Albrecht Werner Popp, Nadshathra Varathan, Helene Buffat, Christoph Senn, Romain Perrelet, Kurt Lippuner
The aim of the present study was to document the changes in bone mineral density (BMD) 1 year after denosumab loss-of-effect following long-term treatment with subcutaneous denosumab 60 mg Q6M during 7 or 10 years and in the absence of any treatment with a bone active substance. All postmenopausal women with osteoporosis who participated to the randomized placebo-controlled FREEDOM core trial and its open-label extension at the University Hospital of Bern, Switzerland, and who accepted to undergo off-treatment follow-up during 1 year after discontinuation, were included (N = 12)...
January 29, 2018: Calcified Tissue International
https://www.readbyqxmd.com/read/29232486/an-essential-warning
#14
Benjamin Z Leder
No abstract text is available yet for this article.
February 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29230512/rebound-associated-vertebral-fractures-after-discontinuation-of-denosumab-for-the-treatment-of-maxillitis
#15
R Niimi, T Kono, A Nishihara, M Hasegawa, T Kono, A Sudo
We reported a 69-year-old female who discontinued denosumab due to dental treatment and subsequently suffered rebound-associated vertebral fractures 10 months after the last injection. This case raised an alarm regarding the discontinuation of denosumab for dental treatment. Denosumab, a human monoclonal antibody administered by subcutaneous injection, to the best of our knowledge, is the only fully investigated inhibitor of receptor activator of nuclear factor kappa B ligand. Discontinuation of denosumab leads to bone turnover rebound and rapid bone mineral density loss...
March 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29196083/the-good-and-the-bad-about-the-2017-american-college-of-physicians-osteoporosis-guidelines
#16
Violet Lagari, Tara Gavcovich, Silvina Levis
PURPOSE: The American College of Physicians (ACP) published a set of guidelines on how to prevent fractures in men and women with low bone density or osteoporosis. As the population ages, the overall risk of fractures increases, thus burdening the health care system. These guidelines review current evidence for osteoporosis management, providing an update to the previous 2008 ACP's guidelines. METHODS: The ACP put forth 6 recommendations addressing the complexities in osteoporosis management based on evidence available through October 2016 with a focus on bisphosphonates, calcium, vitamin D, and estrogen...
January 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/29187046/denosumab-improves-bone-mineral-density-in-patients-with-intestinal-failure-receiving-home-parenteral-nutrition-results-from-a-randomized-controlled-clinical-trial
#17
Kinga Szczepanek, Michal Pedziwiatr, Stanisław Klek
AIM: Low bone mineral density (BMD) is commonly reported in patients receiving home parenteral nutrition (HPN). Oral and intravenous calcium, vitamin D, and bisphosphonates have been used to treat BMD but with low efficiency due to their limited absorption and patient compliance. Denosumab is a new drug that helps prevent osteoclast development and activation and led to decreased bone resorption in some studies. The aim of this study was to assess its value in HPN patients. METHODS: Between November 2011 and March 2013, 49 patients receiving HPN (29 women, 20 men, mean age 55...
March 1, 2017: JPEN. Journal of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/29181213/therapeutic-management-of-a-substantial-pelvic-aneurysmatic-bone-cyst-including-the-off-label-use-of-denosumab-in-a-35-year-old-female-patient
#18
D Ntalos, M Priemel, C Schlickewei, D M Thiesen, J M Rueger, A S Spiro
Aneurysmal bone cysts (ABC) are benign bone tumors, which are highly vascularized. The main course of treatment is curettage followed by bone grafting or cement insertion. Still recurrence remains a main problem for patients. Denosumab is a monoclonal antibody, which acts as an inhibitor of the RANK/RANKL pathway, diminishing bone turnover. Recent case reports have shown that Denosumab can be a promising therapeutic agent for people suffering from therapy-resistant ABC. We report the case of a 35-year-old female patient presenting with a pronounced ABC of the pelvis...
2017: Case Reports in Orthopedics
https://www.readbyqxmd.com/read/29105841/vertebral-fractures-after-discontinuation-of-denosumab-a-post-hoc-analysis-of-the-randomized-placebo-controlled-freedom-trial-and-its-extension
#19
Steven R Cummings, Serge Ferrari, Richard Eastell, Nigel Gilchrist, Jens-Erik Beck Jensen, Michael McClung, Christian Roux, Ove Törring, Ivo Valter, Andrea T Wang, Jacques P Brown
Denosumab reduces bone resorption and vertebral and nonvertebral fracture risk. Denosumab discontinuation increases bone turnover markers 3 months after a scheduled dose is omitted, reaching above-baseline levels by 6 months, and decreases bone mineral density (BMD) to baseline levels by 12 months. We analyzed the risk of new or worsening vertebral fractures, especially multiple vertebral fractures, in participants who discontinued denosumab during the FREEDOM study or its Extension. Participants received ≥2 doses of denosumab or placebo Q6M, discontinued treatment, and stayed in the study ≥7 months after the last dose...
February 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29083977/examining-the-effect-of-medication-adherence-on-risk-of-subsequent-fracture-among-women-with-a-fragility-fracture-in-the-u-s-medicare-population
#20
Allison Keshishian, Natalie Boytsov, Russel Burge, Kelly Krohn, Louise Lombard, Xiang Zhang, Lin Xie, Onur Baser
BACKGROUND: In the United States, osteoporosis affects approximately 10 million people, of whom 80% are women, and it contributes a significant clinical burden to the community. Poor adherence to osteoporosis medications adds to the overall burden of illness. OBJECTIVE: To examine the association of osteoporosis medication adherence and the risk of a subsequent fracture among Medicare-enrolled women with a previous fragility fracture. METHODS: This study was a retrospective observational analysis of U...
November 2017: Journal of Managed Care & Specialty Pharmacy
keyword
keyword
55045
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"